Literature DB >> 22573905

Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease.

Yoshiki Matsuo1, Takashi Kubo, Yasushi Okumoto, Kohei Ishibashi, Kenichi Komukai, Takashi Tanimoto, Yasushi Ino, Hironori Kitabata, Kumiko Hirata, Toshio Imanishi, Hideharu Akagi, Takashi Akasaka.   

Abstract

AIMS: The importance of oxidized low-density lipoprotein (oxLDL) has been implicated in the process of plaque rupture. However, few previous studies demonstrated the relationship between plaque morphology and oxLDL. We evaluated the relationship between coronary plaque vulnerability assessed by optical coherence tomography (OCT) and circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL). METHODS AND
RESULTS: OCT was used to determine plaque vulnerability in 102 patients with acute coronary syndrome (ACS; n = 53) and stable angina pectoris (SAP; n = 49). Circulating levels of MDA-LDL were measured by using enzyme-linked immunosorbent assay. Thin-cap fibroatheromas (TCFAs; defined as lipid-rich with plaque cap thickness <65 μm) were detected more frequently in ACS than in SAP (83% vs. 16%, P < 0.001). The circulating levels of MDA-LDL were significantly higher in patients with ACS compared with SAP (P = 0.008). The levels of MDA-LDL were significantly higher in SAP patients with TCFA than those with non-TCFA (P < 0.001). Although the levels of MDA-LDL were not significant between ACS patients with TCFA and those with non-TCFA, patients with ruptured TCFA had higher levels of MDA-LDL compared with those with morphologically intact TCFA (P = 0.023). MDA-LDL levels were associated with the presence of TCFA (odds ratio, 1.45 per 10-unit increment of MDA-LDL; 95% CI, 1.24-1.68; P< 0.001) in multivariable logistic regression analysis.
CONCLUSION: Circulating MDA-LDL levels might be associated with the presence of TCFA in the culprit lesion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573905     DOI: 10.1093/ehjci/jes094

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  5 in total

1.  Impact of malondialdehyde-modified low-density lipoprotein on coronary plaque vulnerability in patients not receiving lipid-lowering therapy: a whole coronary analysis with multislice-computed tomography.

Authors:  Tsuyoshi Ito; Taku Ichihashi; Hiroshi Fujita; Tomonori Sugiura; Nobuyuki Ohte
Journal:  Heart Vessels       Date:  2017-10-24       Impact factor: 2.037

Review 2.  Oxidative Stress in Human Atherothrombosis: Sources, Markers and Therapeutic Targets.

Authors:  Jose Luis Martin-Ventura; Raquel Rodrigues-Diez; Diego Martinez-Lopez; Mercedes Salaices; Luis Miguel Blanco-Colio; Ana M Briones
Journal:  Int J Mol Sci       Date:  2017-11-03       Impact factor: 5.923

3.  Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a).

Authors:  Tina Z Khan; Adam Hartley; Dorian Haskard; Mikhail Caga-Anan; Dudley J Pennell; Peter Collins; Mahmoud Barbir; Ramzi Khamis
Journal:  Antioxidants (Basel)       Date:  2021-01-18

4.  Cardioprotective Effect of Acetylsalicylic Acid in the Myocardial Ischemia-Reperfusion Model on Oxidative Stress Markers Levels in Heart Muscle and Serum.

Authors:  Piotr Frydrychowski; Marcin Michałek; Iwona Bil-Lula; Elżbieta Chełmecka; Alina Kafel; Agnieszka Noszczyk-Nowak; Dominika Stygar
Journal:  Antioxidants (Basel)       Date:  2022-07-23

5.  Oxidants and antioxidants in myocardial infarction (MI): Investigation of ischemia modified albumin, malondialdehyde, superoxide dismutase and catalase in individuals diagnosed with ST elevated myocardial infarction (STEMI) and non-STEMI (NSTEMI).

Authors:  Nesim Aladağ; Ramazan Asoğlu; Mahmut Ozdemir; Emin Asoğlu; Atabey Rukiye Derin; Canan Demir; Halit Demir
Journal:  J Med Biochem       Date:  2021-06-05       Impact factor: 3.402

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.